New Health Initiatives Announced by Trump Administration: Autism Treatment and Beauty Safety Measures
President Donald J. Trump and Health and Human Services Secretary Robert F. Kennedy Jr. announced bold new health initiatives on September 22, 2025, addressing the autism epidemic that now affects 1 in 31 American children. The FDA published a Federal Register notice for leucovorin label updates for cerebral folate deficiency associated with autism, establishing the first FDA-recognized therapeutic pathway for children with cerebral folate deficiency and autistic symptoms.
In a significant move affecting the beauty and wellness industry, the administration also addressed acetaminophen (Tylenol) safety during pregnancy. The FDA will issue physician notices and begin safety label changes based on studies suggesting potential associations between acetaminophen use during pregnancy and adverse neurodevelopmental outcomes. HHS will launch a nationwide public service campaign to inform families about these potential risks.
These announcements represent major policy shifts that could impact both healthcare providers and consumers, particularly pregnant women who commonly use acetaminophen products during pregnancy.